UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 12, 2019
Date of Report (Date of earliest event reported)
HELIUS MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|
DELAWARE |
001-38445 |
36-4787690 |
|
(State or other jurisdiction of |
(Commission |
(I.R.S. Employer |
|
incorporation or organization) |
File Number) |
Identification No.) |
(Exact name of registrant as specified in charter)
642 Newtown Yardley Road, Suite 100
Newtown, Pennsylvania, 18940
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (215) 944-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a12) |
|
|
☐ |
Precommencement communications pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b)) |
|
|
☐ |
Precommencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
|
|
|
|
|
|
Title of each class |
|
Trading symbol |
|
Name of each exchange on which registered |
|
Class A Common Stock |
|
HSDT |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b‑2 of the Securities Exchange Act of 1934 (§240.12b‑2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☑
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 12, 2019, Helius Medical Technologies, Inc. (the “ Company ”) held its 2019 annual meeting of stockholders (the “ Annual Meeting ”). The stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2019. Of the 25,866,211 shares of Class A Common Stock outstanding as of the record date, 15,476,277 shares, or 59.83%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.
Proposal No. 1 : Election of seven directors of the Company to serve until the 2020 annual meeting of stockholders of the Company and until their respective successors are elected and qualified. The votes were cast as follows:
|
Name |
|
Votes For |
|
Votes Withheld |
|
||
|
Philippe Deschamps |
|
11,143,698 |
|
63,752 |
|
||
|
Dane C. Andreeff |
|
10,930,030 |
|
277,420 |
|
||
|
Thomas E. Griffin |
|
|
11,175,633 |
|
31,817 |
|
|
|
Huaizheng Peng |
|
11,073,143 |
|
134,307 |
|
||
|
Edward M. Straw |
|
|
11,149,306 |
|
58,144 |
|
|
|
Mitchell E. Tyler |
|
11,176,198 |
|
31,252 |
|
||
|
Blane Walter |
|
|
10,609,048 |
|
603,402 |
|
|
Broker Non-Votes: 4,268,827
All nominees were elected.
Proposal No. 2 : Ratification of the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. The votes were cast as follows:
|
|
|
Votes For |
|
Votes Against |
|
Abstained |
|
|
Ratification of Selection of BDO USA, LLP |
|
15,429,313 |
|
14 |
|
46,950 |
|
The selection of BDO USA, LLP was ratified.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized .
|
|
HELIUS MEDICAL TECHNOLOGIES, INC. |
|
|
|
|
|
|
Dated: June 13, 2019 |
By: |
/s/ Joyce LaViscount |
|
|
|
Joyce LaViscount, Chief Financial Officer |
|
|
|
|